open access

Vol 79, No 5 (2021)
Review paper
Get Citation

Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction?

Dirk von Lewinski, Martin Benedikt, Norbert Tripolt, Markus Wallner, Harald Sourij, Ewald Kolesnik
DOI: 10.33963/KP.15969
·
Pubmed: 34125922
·
Kardiol Pol 2021;79(5):503-509.

open access

Vol 79, No 5 (2021)
Review article

Abstract

The sodium-glucose cotransporter 2 inhibitors (SGLT2i), empagliflozin, dapagliflozin, and canagliflozin, have shown impressive beneficial effects in patients with type 2 diabetes mellitus in mandatory cardiovascular outcome trials. Retrospective data analysis revealed signals that pointed towards positive effects independent of the antidiabetic effects. This could be confirmed for empagliflozin and dapagliflozin in chronic heart failure with reduced ejection fraction alone, where rates of hospitalization for heart failure and cumulative major adverse cardiovascular events were reduced to a similar extent in patients with and without diabetes mellitus as in corresponding outcome trials. Cardiac remodeling following myocardial infarction leads to heart failure with reduced ejection fraction in many patients and aggravates morbidity and mortality. Clinical data of SGLT2i treatment after acute myocardial infarction is sparse. This review focuses on available experimental data on the effects of SGLT2i used before, during, and after myocardial infarction as well as already published and currently ongoing clinical trials.

Abstract

The sodium-glucose cotransporter 2 inhibitors (SGLT2i), empagliflozin, dapagliflozin, and canagliflozin, have shown impressive beneficial effects in patients with type 2 diabetes mellitus in mandatory cardiovascular outcome trials. Retrospective data analysis revealed signals that pointed towards positive effects independent of the antidiabetic effects. This could be confirmed for empagliflozin and dapagliflozin in chronic heart failure with reduced ejection fraction alone, where rates of hospitalization for heart failure and cumulative major adverse cardiovascular events were reduced to a similar extent in patients with and without diabetes mellitus as in corresponding outcome trials. Cardiac remodeling following myocardial infarction leads to heart failure with reduced ejection fraction in many patients and aggravates morbidity and mortality. Clinical data of SGLT2i treatment after acute myocardial infarction is sparse. This review focuses on available experimental data on the effects of SGLT2i used before, during, and after myocardial infarction as well as already published and currently ongoing clinical trials.

Get Citation

Keywords

sodium-glucose cotransporter 2 inhibitors, myocardial infarction, metabolism, clinical trials

About this article
Title

Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction?

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 79, No 5 (2021)

Article type

Review paper

Pages

503-509

DOI

10.33963/KP.15969

Pubmed

34125922

Bibliographic record

Kardiol Pol 2021;79(5):503-509.

Keywords

sodium-glucose cotransporter 2 inhibitors
myocardial infarction
metabolism
clinical trials

Authors

Dirk von Lewinski
Martin Benedikt
Norbert Tripolt
Markus Wallner
Harald Sourij
Ewald Kolesnik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl